CN113272304B - Akt抑制剂 - Google Patents

Akt抑制剂 Download PDF

Info

Publication number
CN113272304B
CN113272304B CN202080005749.9A CN202080005749A CN113272304B CN 113272304 B CN113272304 B CN 113272304B CN 202080005749 A CN202080005749 A CN 202080005749A CN 113272304 B CN113272304 B CN 113272304B
Authority
CN
China
Prior art keywords
compound
formula
pharmaceutically acceptable
methyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080005749.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113272304A (zh
Inventor
马昌友
田禾
安杰
赵建良
陈东晖
吴舰
徐丹
朱春霞
田舟山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Original Assignee
Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd filed Critical Nanjing Chia Tai Tianqing Pharmaceutical Co Ltd
Priority to CN202410142331.2A priority Critical patent/CN117964620A/zh
Publication of CN113272304A publication Critical patent/CN113272304A/zh
Application granted granted Critical
Publication of CN113272304B publication Critical patent/CN113272304B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080005749.9A 2019-01-29 2020-01-22 Akt抑制剂 Active CN113272304B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410142331.2A CN117964620A (zh) 2019-01-29 2020-01-22 Akt抑制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019100848013 2019-01-29
CN201910084801 2019-01-29
PCT/CN2020/073798 WO2020156437A1 (zh) 2019-01-29 2020-01-22 Akt抑制剂

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410142331.2A Division CN117964620A (zh) 2019-01-29 2020-01-22 Akt抑制剂

Publications (2)

Publication Number Publication Date
CN113272304A CN113272304A (zh) 2021-08-17
CN113272304B true CN113272304B (zh) 2024-03-29

Family

ID=71841634

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080005749.9A Active CN113272304B (zh) 2019-01-29 2020-01-22 Akt抑制剂
CN202410142331.2A Pending CN117964620A (zh) 2019-01-29 2020-01-22 Akt抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410142331.2A Pending CN117964620A (zh) 2019-01-29 2020-01-22 Akt抑制剂

Country Status (10)

Country Link
US (1) US12617784B2 (cg-RX-API-DMAC7.html)
EP (1) EP3919491B1 (cg-RX-API-DMAC7.html)
JP (2) JP7617005B2 (cg-RX-API-DMAC7.html)
KR (1) KR102892239B1 (cg-RX-API-DMAC7.html)
CN (2) CN113272304B (cg-RX-API-DMAC7.html)
AU (1) AU2020214258B2 (cg-RX-API-DMAC7.html)
CA (1) CA3127884A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037595T3 (cg-RX-API-DMAC7.html)
PL (1) PL3919491T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020156437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023520140A (ja) * 2020-03-17 2023-05-16 江蘇恒瑞医薬股▲ふん▼有限公司 縮合二環系誘導体、その調製方法及びその医薬的応用
CN115485276B (zh) * 2020-05-15 2024-05-31 南京正大天晴制药有限公司 氘代akt激酶抑制剂
US12673061B2 (en) 2020-07-22 2026-07-07 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Unit dosage composition of AKT inhibitor
EP4186902A4 (en) * 2020-07-22 2024-06-05 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE SALT, PREPARATION METHOD AND USE THEREOF
JP7472391B2 (ja) * 2020-07-22 2024-04-22 南京正大天晴制薬有限公司 ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩及び結晶形
CN116478156A (zh) * 2022-01-17 2023-07-25 南京正大天晴制药有限公司 一种akt抑制剂化合物的富马酸盐晶型及其制备方法
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
CN121586576A (zh) 2023-06-14 2026-02-27 南京正大天晴制药有限公司 Akt抑制剂在制备预防或治疗乳腺癌药物中的用途
CN120157686A (zh) * 2023-12-14 2025-06-17 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用
CN121177294B (zh) * 2025-11-27 2026-02-27 四川省医学科学院·四川省人民医院 Akt抑制剂在制备诱导胰岛移植免疫耐受药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882347A (zh) * 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
WO2009089462A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
CN101578273A (zh) * 2006-07-06 2009-11-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶
CN105051043A (zh) * 2012-11-16 2015-11-11 默克专利有限公司 用作激酶活性调节剂的新颖的杂环类衍生物
CN109020957A (zh) * 2017-06-12 2018-12-18 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2481336C2 (ru) * 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US20130065908A1 (en) * 2009-12-07 2013-03-14 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
AR093511A1 (es) * 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas
EP3189036B1 (en) * 2014-09-05 2023-07-19 ArQule, Inc. Compositions and methods for treating proliferation disorders
CN108503645A (zh) * 2018-03-01 2018-09-07 山东大学 含氨甲基的哌嗪酮类化合物及其制备方法和应用
EP3784669B1 (en) * 2018-04-24 2023-10-25 Vertex Pharmaceuticals Incorporated Pteridinone compounds and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1882347A (zh) * 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
CN101578273A (zh) * 2006-07-06 2009-11-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶
WO2009089462A1 (en) * 2008-01-09 2009-07-16 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
CN105051043A (zh) * 2012-11-16 2015-11-11 默克专利有限公司 用作激酶活性调节剂的新颖的杂环类衍生物
CN109020957A (zh) * 2017-06-12 2018-12-18 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物

Also Published As

Publication number Publication date
KR102892239B1 (ko) 2025-11-26
JP2022517866A (ja) 2022-03-10
CN117964620A (zh) 2024-05-03
KR20210120054A (ko) 2021-10-06
EP3919491A4 (en) 2022-10-19
AU2020214258B2 (en) 2025-08-28
PL3919491T3 (pl) 2025-10-20
US12617784B2 (en) 2026-05-05
EP3919491B1 (en) 2025-05-28
US20220144821A1 (en) 2022-05-12
EP3919491C0 (en) 2025-05-28
CA3127884A1 (en) 2020-08-06
AU2020214258A1 (en) 2021-09-16
ES3037595T3 (en) 2025-10-03
WO2020156437A1 (zh) 2020-08-06
JP7617005B2 (ja) 2025-01-17
EP3919491A1 (en) 2021-12-08
CN113272304A (zh) 2021-08-17
JP2024175091A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
JP7617005B2 (ja) Akt阻害剤
AU2020337938B2 (en) KRas G12D inhibitors
TWI841200B (zh) 雜環類化合物、藥物組成物及其應用
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CA3217830A1 (en) 2-aminobenzothiazole compounds and methods of use thereof
TW202417455A (zh) 新穎三雜環化合物及藥學組成物
ES2871524T3 (es) Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
CA3198885A1 (en) Azaquinazoline pan-kras inhibitors
WO2016007185A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
WO2011152485A1 (ja) 新規4,5-縮環ピリミジン誘導体
CN115916350B (zh) Akt抑制剂的单位剂量组合物
CN115485276B (zh) 氘代akt激酶抑制剂
US20250320213A1 (en) Nitrogen-Containing Heterocyclic Compounds
HK40050826A (en) Akt inhibitor
HK40050826B (en) Akt inhibitor
AU2021326929A9 (en) Aromatic ring-lactam compound, preparation method therefor and use thereof
WO2024086939A1 (en) Purine compounds, compositions comprising them and uses thereof
EP4727945A1 (en) 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octane derivatives as smarca2 degrading protacs for the treatment of cancer
EA053265B1 (ru) Тетрагетероциклическое соединение
HK40029944A (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40029944B (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050826

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant